Advertisement

Organisation › Details
ARCH Venture (Group)
ARCH Venture Partners is one of the largest early stage technology venture firms in the U.S. ARCH has co-founded and provided initial investments for more than 250 companies organized around innovations from research universities, national laboratories, corporate research groups and entrepreneurs. By focusing on leading scientific innovators, ARCH has been at the forefront of investing in major areas of innovation in the life sciences and physical sciences, and has helped to catalyze revolutionary advances in genomics, nanotechnology, industrial biotechnology and major disease treatments. ARCH has raised ten primary funds with combined committed capital at the time raised of approximately $4.5 billion. *
![]() |
Start | 1986-01-01 established |
Today | ARCH Venture Partners | |
![]() |
Industry | venture capital |
![]() |
Person | Crandell, Keith (ARCH Venture Partners 201302 Managing Director + Co-founder) |
Person 2 | Gillis, Steven (ARCH Venture Partners 200603 Venture Partner before co-founder + CEO Corixa before co-founder Immunex) | |
![]() |
Region | Chicago, IL |
Country | United States (USA) | |
Street | 8725 W. Higgins Road. Suite 290 | |
City | 60631 Chicago, IL | |
Tel | +1-773-380-6600 | |
Address record changed: 2022-04-17 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 2,500,000,000 (funds, managed 2017-03-16) | |
* Document for »About Section«: Vizgen. (1/30/20). "Press Release: Vizgen Launches with $14M Series A Financing Led by ARCH Venture Partners and Northpond Ventures". Cambridge, MA. | ||
Record changed: 2022-04-17 |
Advertisement

More documents for ARCH Venture (Group)
- [1] Seaport Therapeutics. (4/9/24). "Press Release: Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines". Boston, MA....
- [2] Mirador Therapeutics, Inc.. (3/21/24). "Press Release: Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases". San Diego, CA....
- [3] AIRNA Corporation. (9/19/23). "Press Release: AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases". Cambridge, MA & Tübingen....
- [4] Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford....
- [5] FogPharma (Fog Pharmaceuticals Inc.). (11/21/22). "Press Release: FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers". Cambridge, MA....
- [6] Pretzel Therapeutics, Inc.. (9/12/22). "Press Release: Pretzel Therapeutics Launches with $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies". Waltham, MA....
- [7] Oxford Nanoimaging Ltd.. (1/20/22). "Press Release: ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital". San Diego, CA & Oxford....
- [8] ARCH Venture Partners. (12/1/21). "Press Release: ARCH Venture Partners Announces Several Key Appointments". Chicago, IL....
- [9] Bit Bio Ltd.. (11/5/21). "Press Release: bit.bio Raises $103 Million in First Close of Series B Financing". Cambridge....
- [10] Dewpoint Therapeutics. (9/29/20). "Press Release: Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs that Target Biomolecular Condensates". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top